Joseph Ciccolini

List of Publications by Year
in descending order

153	4,397	101496	138417
papers	citations	36 h-index	58 g-index

159	159	159	5622
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clinical Pharmacokinetics, 2019, 58, 835-857.	1.6	222
2	Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget, 2011, 2, 797-809.	0.8	189
3	Computational oncology â€" mathematical modelling of drug regimens for precision medicine. Nature Reviews Clinical Oncology, 2016, 13, 242-254.	12.5	174
4	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemotherapy and Pharmacology, 2016, 78, 1-12.	1.1	152
5	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. Cancer Research, 2016, 76, 4931-4940.	0.4	132
6	Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies. Journal of Clinical Oncology, 2010, 28, 160-165.	0.8	115
7	Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 5496-5502.	3.2	98
8	Mathematical Modeling of Tumor Growth and Metastatic Spreading: Validation in Tumor-Bearing Mice. Cancer Research, 2014, 74, 6397-6407.	0.4	96
9	Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs. Critical Reviews in Oncology/Hematology, 2013, 88, 504-513.	2.0	88
10	Increased cytotoxicity and bystander effect of 5-fluorouracil and 5â€²-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. British Journal of Cancer, 1999, 80, 1726-1733.	2.9	84
11	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. PLoS Computational Biology, 2020, 16, e1007178.	1.5	84
12	A Rapid and Inexpensive Method for Anticipating Severe Toxicity to Fluorouracil and Fluorouracil-based Chemotherapy. Therapeutic Drug Monitoring, 2006, 28, 678-685.	1.0	83
13	Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie, 2013, 95, 1233-1238.	1.3	79
14	Molecular mechanisms underlying the interaction between ZD1839 (â€˜Iressaâ€™) and cisplatin/5-fluorouracil. British Journal of Cancer, 2003, 89, 585-592.	2.9	78
15	Liposome-Encapsulated Anticancer Drugs: Still Waiting for the Magic Bullet?. Current Medicinal Chemistry, 2009, 16, 4361-4373.	1.2	78
16	A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 307-315.	0.7	75
17	Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracilâ€"Related Severe Toxicities: Hype or Hope?. Clinical Colorectal Cancer, 2010, 9, 224-228.	1.0	75
18	DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemotherapy and Pharmacology, 2011, 67, 49-56.	1.1	69

#	Article	IF	Citations
19	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. Seminars in Cancer Biology, 2015, 35, 53-61.	4.3	67
20	Antiproliferative Effect of Ascorbic Acid Is Associated with the Inhibition of Genes Necessary to Cell Cycle Progression. PLoS ONE, 2009, 4, e4409.	1.1	65
21	Integrating pharmacogenetics into gemcitabine dosingâ€"time for a change?. Nature Reviews Clinical Oncology, 2011, 8, 439-444.	12.5	63
22	Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil/Capecitabine Therapy. Clinical Colorectal Cancer, 2006, 6, 288-296.	1.0	61
23	Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochemical Pharmacology, 2002, 63, 1831-1842.	2.0	60
24	Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 665-672.	1.5	53
25	Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenetics and Genomics, 2007, 17, 841-844.	0.7	51
26	Toxic death-case after capecitabineÂ+Âoxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemotherapy and Pharmacology, 2006, 58, 272-275.	1.1	49
27	A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. Scientific Reports, 2017, 7, 2714.	1.6	46
28	All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. JCO Oncology Practice, 2020, 16, 793-798.	1.4	46
29	High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anti-Cancer Drugs, 2008, 19, 267-273.	0.7	45
30	Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept. ISRN Pharmaceutics, 2012, 2012, 1-11.	1.0	44
31	Personalized medicine in oncology: where have we come from and where are we going?. Pharmacogenomics, 2013, 14, 931-939.	0.6	43
32	Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenaseâ€driven adaptive dosing of 5â€FU in patients with digestive cancer. British Journal of Clinical Pharmacology, 2016, 81, 124-130.	1.1	43
33	ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clinical Cancer Research, 2003, 9, 4735-42.	3.2	42
34	Thymidine Phosphorylase and Fluoropyrimidines Efficacy: A Jekyl and Hyde Story. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 71-81.	7.0	41
35	Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics, 2013, 14, 1047-1051.	0.6	39
36	Metronomics chemotherapy: time for computational decision support. Cancer Chemotherapy and Pharmacology, 2014, 74, 647-652.	1.1	37

#	Article	IF	Citations
37	Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemotherapy and Pharmacology, 2009, 63, 1177-1180.	1.1	36
38	Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy. Cancer Research, 2017, 77, 4723-4733.	0.4	36
39	Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. International Journal of Nanomedicine, 2018, Volume 13, 3451-3465.	3.3	36
40	5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. Cancer Chemotherapy and Pharmacology, 2011, 68, 823-826.	1.1	35
41	Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology. Critical Reviews in Oncology/Hematology, 2018, 129, 1-12.	2.0	35
42	Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?. Trends in Pharmacological Sciences, 2007, 28, 597-598.	4.0	33
43	Therapeutic Drug Monitoring for Dose Individualization of Cisplatin in Testicular Cancer Patients Based Upon Total Platinum Measurement in Plasma. Therapeutic Drug Monitoring, 2006, 28, 532-539.	1.0	31
44	COVID-19 vaccine race: watch your step for cancer patients. British Journal of Cancer, 2021, 124, 860-861.	2.9	31
45	Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Molecular Cancer Therapeutics, 2005, 4, 1962-1971.	1.9	27
46	From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. International Journal of Nanomedicine, 2018, Volume 13, 6677-6688.	3.3	27
47	Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget, 2017, 8, 23087-23098.	0.8	26
48	Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients. Oncotarget, 2017, 8, 47161-47166.	0.8	26
49	Sudden Death Related to Toxicity in a Patient on Capecitabine and Irinotecan Plus Bevacizumab Intake: Pharmacogenetic Implications. Journal of Clinical Oncology, 2012, 30, e41-e44.	0.8	25
50	Dose Individualization of Carboplatin After a 120-hour Infusion Schedule: Higher Dose Intensity but Fewer Toxicities. Therapeutic Drug Monitoring, 2006, 28, 212-218.	1.0	23
51	A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology. Comptes Rendus Mathematique, 2012, 350, 23-28.	0.1	23
52	Biodistribution, Tumor Uptake and Efficacy of 5-FU-Loaded Liposomes: Why Size Matters. Pharmaceutical Research, 2014, 31, 2677-2684.	1.7	23
53	Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. Biomarker Insights, 2016, 11, BMI.S33372.	1.0	23
54	CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Advances, 2018, 2, 462-469.	2.5	23

#	Article	IF	Citations
55	Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. Vaccines, 2020, 8, 632.	2.1	23
56	Lack of contribution of dihydrofluorouracil and Î±-fluoro-Î²-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes. Anti-Cancer Drugs, 2004, 15, 969-974.	0.7	22
57	A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. BMC Cancer, 2016, 16, 278.	1.1	22
58	Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 2- Application to Head-and-Neck Cancer Patients. Clinical Cancer Drugs, 2018, 4, 122-128.	0.3	22
59	Î±â€hederin potentiates 5â€FU antitumor activity in human colon adenocarcinoma cells. Phytotherapy Research, 2008, 22, 1299-1302.	2.8	21
60	Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment. Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 403-412.	0.4	21
61	Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. European Respiratory Review, 2018, 27, 170098.	3.0	21
62	Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1-9.	1.5	21
63	Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Diagnostics, 2022, 12, 286.	1.3	20
64	Cytotoxic Effects of Haplamine and its Major Metabolites on Human Cancer Cell Lines. Planta Medica, 2008, 74, 1265-1268.	0.7	19
65	High-Resolution Melting Analysis of Sequence Variations in the Cytidine Deaminase Gene (CDA) in Patients With Cancer Treated With Gemcitabine. Therapeutic Drug Monitoring, 2010, 32, 53-60.	1.0	19
66	Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy. Clinical Pharmacokinetics, 2016, 55, 1015-1025.	1.6	19
67	Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations. Anticancer Research, 2016, 36, 6051-6058.	0.5	19
68	Population Pharmacokinetics of Etoposide: Application to Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2002, 24, 709-714.	1.0	18
69	Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles. Expert Review of Clinical Pharmacology, 2018, 11, 599-610.	1.3	18
70	Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacology Research and Perspectives, 2021, 9, e00757.	1.1	18
71	Development of Stealth Liposome Formulation of 2â€²-Deoxyinosine as 5-Fluorouracil Modulator: In Vitro and In Vivo Study. Pharmaceutical Research, 2005, 22, 2051-2057.	1.7	17
72	Genotype-Based Methods for Anticipating Gemcitabine-Related Severe Toxicities May Lead to False-Negative Results. Journal of Clinical Oncology, 2007, 25, 4855-4855.	0.8	17

#	Article	IF	Citations
73	CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics, 2012, 13, 393-397.	0.6	17
74	In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling. Scientific Reports, 2016, 6, 36173.	1.6	17
75	Revisiting Bevacizumabâ€‰+â€‰Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Nonâ€Small Cell Lung Carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 42-50.	1.3	17
76	Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. Pharmacogenomics, 2015, 16, 1907-1912.	0.6	16
77	FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. PLoS ONE, 2015, 10, e0135907.	1.1	16
78	Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Molecular Cancer Therapeutics, 2002, 1, 923-7.	1.9	16
79	Monitoring of the intracellular activation of 5â€fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study. Fundamental and Clinical Pharmacology, 2000, 14, 147-154.	1.0	15
80	Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity. Current Topics in Medicinal Chemistry, 2012, 12, 1713-1719.	1.0	15
81	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. Clinical Cancer Research, 2017, 23, 7171-7179.	3.2	15
82	Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. Pharmaceutics, 2020, 12, 1166.	2.0	15
83	Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations. Clinical Pharmacology and Therapeutics, 2020, 108, 458-470.	2.3	15
84	Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anti-Cancer Drugs, 2020, 31, 463-472.	0.7	14
85	Pharmacogenetics and breast cancer management: current status and perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 719-729.	1.5	13
86	DPD deficiency in patients treated with fluorouracil. Lancet Oncology, The, 2015, 16, 1574-1576.	5.1	13
87	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals, 2021, 14, 796.	1.7	13
88	Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. Anti-Cancer Drugs, 2006, 17, 463-470.	0.7	12
89	A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. British Journal of Clinical Pharmacology, 2008, 65, 966-970.	1.1	12
90	In Vitro and In Vivo Evaluation of Lipofufol, a New Triple Stealth Liposomal Formulation of Modulated 5-Fu: Impact on Efficacy and Toxicity. Pharmaceutical Research, 2013, 30, 1281-1290.	1.7	12

#	Article	IF	Citations
91	A Simple and Rapid UPLCâ€UV Method for Detecting DPD Deficiency in Patients With Cancer. Clinical and Translational Science, 2020, 13, 761-768.	1.5	12
92	Lethal toxicity after administration of azacytidine. Pharmacogenetics and Genomics, 2015, 25, 317-321.	0.7	12
93	Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Fundamental and Clinical Pharmacology, 2012, 26, 530-537.	1.0	11
94	Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3453-E3453.	3.3	11
95	A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1138, 121968.	1.2	11
96	Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC. British Journal of Cancer, 2020, 123, 337-338.	2.9	10
97	Nucleoside analogs: ready to enter the era of precision medicine?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 865-877.	1.5	9
98	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. Therapeutic Drug Monitoring, 2019, 41, 142-159.	1.0	9
99	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. JCO Precision Oncology, 2020, 4, 486-491.	1.5	9
100	Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs. Anti-Cancer Drugs, 2005, 16, 675-682.	0.7	8
101	Successful treatment of post-transplant Epsteinâ€“Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. Leukemia and Lymphoma, 2012, 53, 2063-2065.	0.6	8
102	Gender, Cytidine Deaminase, and 5-Aza/Decitabineâ€”Letter. Clinical Cancer Research, 2013, 19, 3105-3105.	3.2	8
103	Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. Pharmacogenomics, 2019, 20, 931-938.	0.6	8
104	Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Nonâ€Small Cell Lung Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 577-586.	1.3	8
105	Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clinical Cancer Research, 2003, 9, 102-8.	3.2	8
106	Taxotere???5???-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells. Anti-Cancer Drugs, 2005, 16, 309-316.	0.7	7
107	Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. European Journal of Clinical Pharmacology, 2010, 66, 959-960.	0.8	7
108	A CDD Polymorphism as Predictor of Capecitabine-Induced Handâ€“Foot Syndromeâ€”Letter. Clinical Cancer Research, 2012, 18, 317-317.	3.2	7

#	Article	IF	Citations
109	Women at a Disadvantage in Fluorouracil Treatment. JAMA Oncology, 2016, 2, 829.	3.4	7
110	Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1126-1127, 121770.	1.2	7
111	Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. British Journal of Clinical Pharmacology, 2019, 85, 1213-1214.	1.1	7
112	Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?. Current Drug Targets, 2014, 15, 1200-1204.	1.0	7
113	Validation of a simple HPLC method for assay of haplamine and its metabolites in plasma suitable for pharmacokinetic application in rats. Biomedical Chromatography, 2008, 22, 125-130.	0.8	6
114	Monoclonal antibodies for treating gastric cancer: promises and pitfalls. Expert Opinion on Biological Therapy, 2016, 16, 759-769.	1.4	6
115	Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. Anticancer Research, 2019, 39, 3419-3422.	0.5	6
116	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. Pharmaceutics, 2020, 12, 758.	2.0	6
117	Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib. Pharmaceuticals, 2021, 14, 494.	1.7	6
118	Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?. Pediatric Blood and Cancer, 2010, 54, 781-782.	0.8	5
119	Severe or lethal toxicities with nucleosidic analogs: time for action. Pharmacogenomics, 2013, 14, 227-230.	0.6	5
120	Prevention of 5-fluorouracilâ€“induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. Seminars in Oncology, 2017, 44, 159-160.	0.8	5
121	Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. Pharmacogenomics, 2020, 21, 173-179.	0.6	5
122	Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxelâ€“erlotinib and 5-fluoro-5â€²-deoxyuridine. Anti-Cancer Drugs, 2006, 17, 807-813.	0.7	4
123	Reply to E. Giovannetti et al. Journal of Clinical Oncology, 2010, 28, e223-e225.	0.8	4
124	Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant. Pharmacogenetics and Genomics, 2014, 24, 527-529.	0.7	4
125	Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report. Pharmacogenomics, 2015, 16, 677-679.	0.6	4
126	Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. Therapeutic Drug Monitoring, 2017, 39, 290-296.	1.0	4

#	Article	IF	Citations
127	Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2019, 41, 66-74.	1.0	4
128	Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. Journal of Controlled Release, 2021, 338, 244-252.	4.8	4
129	Editorial [Hot Topic: Targeted Therapy, Targeted Dosing and Targeted Delivery in Oncology: Where Do We Stand?]. Current Topics in Medicinal Chemistry, 2012, 12, 1638-1638.	1.0	3
130	Mechanistic models for hematological toxicities: Small is beautiful. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 396-398.	1.3	3
131	Detecting DPD deficiency: when perfect is the enemy of good. Cancer Chemotherapy and Pharmacology, 2021, 87, 717-719.	1.1	3
132	Multicentric phase II trial of TIâ€CE highâ€dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Medicine, 2021, 10, 2250-2258.	1.3	3
133	Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxics modalities: application to the bevacizumab-paclitaxel association in breast cancer models. , 2014, , .		3
134	An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study. British Journal of Radiology, 2016, 89, 20160061.	1.0	2
135	Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a modelâ€based population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology, 2022, 90, 29-44.	1.1	2
136	100% Human Monoclonal Antibodies in Oncology: Hype or Breakthrough?. Current Topics in Medicinal Chemistry, 2012, 12, 1643-1648.	1.0	1
137	PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine. Cancer Chemotherapy and Pharmacology, 2017, 80, 1265-1266.	1.1	1
138	Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor. Lecture Notes in Computer Science, 2019, , 87-97.	1.0	1
139	Abstract 1869: Severe toxicities in patients undergoing gemcitabine, ARA-C, capecitabine, or azacytidine treatments: Is deregulated cytidine deaminase the bad guy. , 2012, , .		1
140	Abstract 5555: Pharmacogenetics-pharmacokinetics study of bevacizumab in mCRC patients treated with Avastin-Folfiri regimen: Search for predictive markers of response and study of the pharmacokinetics variability. , 2014, , .		1
141	Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer. , 2008, , 249-265.		1
142	Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point. Cancer Chemotherapy and Pharmacology, 2022, 89, 565-569.	1.1	1
143	Research Highlights: Highlights from the latest articles in pharmacogenomics applied to cancer therapy. Pharmacogenomics, 2013, 14, 1007-1009.	0.6	0
144	Research Highlights: Highlights from the latest articles in pharmacogenomics. Pharmacogenomics, 2013, 14, 1137-1139.	0.6	0

#	Article	IF	Citations
145	Ang1 and Tie2 Are Predictive Biomarkers for Bevacizumabâ€"Letter. Clinical Cancer Research, 2015, 21, 934-934.	3.2	0
146	Pharmacokinetics and Pharmacogenetics of Metronomics. , 2016, , 189-207.		0
147	The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?. Translational Oncology, 2021, 14, 100952.	1.7	0
148	Title is missing!. , 2020, 16, e1007178.		0
149	Title is missing!. , 2020, 16, e1007178.		0
150	Title is missing!. , 2020, 16, e1007178.		0
151	Title is missing!. , 2020, 16, e1007178.		0
152	Title is missing!. , 2020, 16, e1007178.		0
153	Title is missing!. , 2020, 16, e1007178.		0